Development of histone deacetylase inhibitors for cancer treatment.
about
Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literatureHDAC and HDAC Inhibitor: From Cancer to Cardiovascular DiseasesAddressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesThe quest for an effective and safe personalized cell therapy using epigenetic toolsRole of histone deacetylase activity in the developing lateral line neuromast of zebrafish larvae.Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II studySurvivin, a molecular target for therapeutic interventions in squamous cell carcinoma.Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancerOxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies.A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumorsEnvironmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegenerationBlocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy.Enantioselective total synthesis of (+)-largazole, a potent inhibitor of histone deacetylase.Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)Determination of chidamide in rat plasma by LC-MS and its application to pharmacokinetics study.HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escapeEpigenomics and ovarian carcinoma.Paraquat induces epigenetic changes by promoting histone acetylation in cell culture models of dopaminergic degeneration.Metastasis: recent discoveries and novel treatment strategies.Regulation of the proapoptotic factor Bax by Ku70-dependent deubiquitylation.Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancerInvestigation of depth-resolved nanoscale structural changes in regulated cell proliferation and chromatin decondensation.Epigenetic targeting in breast cancer: therapeutic impact and future direction.HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockadeHR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.Histone deacetylase inhibitors in lymphoma and solid malignancies.Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.Epigenetic therapy in human choriocarcinoma.Inhibition of histone acetylation by curcumin reduces alcohol-induced fetal cardiac apoptosis.Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteinsArtemisinin derivatives: a patent review (2006 - present).Epigenetics in osteoarthritis and its implication for future therapeutics.Disruption of the histone acetyltransferase MYST4 leads to a Noonan syndrome-like phenotype and hyperactivated MAPK signaling in humans and mice.Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results.Using zebrafish as a model to study the role of epigenetics in hearing loss.Down-Regulation of Thioredoxin1 Is Involved in Death of Calu-6 Lung Cancer Cells Treated With Suberoyl Bishydroxamic Acid.Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma.Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
P2860
Q26741242-D98D0E7E-8A92-4174-8C19-F7F07635FC4FQ26766640-297080D7-3A8D-49E9-A4BE-04E3AB2C5CB6Q28074716-AAAA6F1B-FBAB-4F98-99F6-C0087A1458F7Q28079389-8B9414DC-36CE-4CBC-A80F-FF60CDCA79A9Q30575262-101271C6-E518-42C6-9524-361A69F71005Q33392042-38D0CC2C-88C6-4B3A-8675-54BC0DAAA698Q33438732-1BB0A7D4-A265-4C66-8A89-7B06484D419DQ33634679-9AB1065C-3350-4C42-A6DC-2DF7FB65A2C1Q33651762-324F115F-A339-48F4-B4E8-C4382B3034DDQ33741142-198A92B5-5ED9-4C3E-9923-A67671CDB6F9Q33752772-91D93046-00A4-4384-9A35-5CAF25AE760CQ33762517-F40B042C-C0D3-4F5E-9D83-DFF2ECF8A547Q33943997-E0C327EC-3CF3-4C79-9A70-AD502C97B62EQ34156653-DAC855CC-8C9F-4587-8BF0-059661A30166Q34510205-57DB60A2-D4F8-4077-82BE-3AE828E9AF55Q34822075-29F4CCDC-1C34-46AB-B080-E730EFB382FCQ35176173-8604594D-7900-4DF6-8F87-5479E9AD2FA1Q35636575-F18733E7-5B60-4E4D-A83C-9626504C079BQ36123405-92166183-209D-4ABE-A31E-54377BE698B8Q36407511-18F9147F-32F9-4C49-8CBD-EF00EC4CDA3FQ36516034-97D38BDD-5F59-4122-B10C-301380CF7680Q36537920-5130B901-79D7-4FC0-B766-2AD67414D019Q36743566-48CE0FDE-024B-4F9E-BB97-9365D93BC842Q36856318-1263EBBB-9A39-4C7D-A021-9FB182D44D5AQ36912547-423F9CCD-C2E9-4CD3-8438-018B7B3C5550Q37002069-964881BB-5A75-4710-BDEC-5E1C8C54CE86Q37118947-72BE5ECA-6426-4A4E-909E-C19D600D8722Q37260402-471F0D98-02A2-4A6E-A293-D35BCE4C58E5Q37334277-B4053BC3-926E-444F-890A-1EB4C2BB5AFAQ37567142-E0472CB5-26F0-40F9-A809-E350A2616608Q37662700-F582E3D3-6CB4-406B-AA11-69AAE44EDC34Q37791830-C1475975-F46E-4EA6-A93D-834FE6F4C6C5Q38042732-6511538D-7AC3-43C8-AC97-CC6C8447AB8DQ38081554-4FEEC400-D4A5-4B7A-A9C2-89FFE3D8F4FAQ38271699-8C368CB2-E429-4540-94E2-3DCF2F89A8A5Q38582589-5AD29753-0B49-4A4B-AB8D-64F3E2453C68Q38691398-375C25DD-08D6-4955-95E5-B03419963BEFQ38828376-0A7F7906-35A5-43BA-BC0E-45CC0757FBD8Q38867200-49E33DB5-2B82-46F3-BF14-D0CFFD2B70E0Q39051716-E2F3E4F6-8E83-493A-A348-53397E8D0FB1
P2860
Development of histone deacetylase inhibitors for cancer treatment.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Development of histone deacetylase inhibitors for cancer treatment.
@en
type
label
Development of histone deacetylase inhibitors for cancer treatment.
@en
prefLabel
Development of histone deacetylase inhibitors for cancer treatment.
@en
P2860
P356
P1476
Development of histone deacetylase inhibitors for cancer treatment.
@en
P2093
Douglas Marchion
Pamela Münster
P2860
P304
P356
10.1586/14737140.7.4.583
P577
2007-04-01T00:00:00Z